Ritter brings scientific excellence, creativity and rigor to delivering cutting edge products and therapies that improve patient’s digestive health.

Primary areas of focus include gastrointestinal physiology, metabolism and gut adaptation associated with gastrointestinal diseases, including lactose intolerance, irritable bowel syndrome, Crohn’s disease and ulcerative colitis.

Ritter’s first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug and therapeutic treatment for lactose intolerance.

Future development efforts will focus on the gastrointestinal conditions, such as irritable bowel syndrome, Crohn's disease and ulcerative colitis.